¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå ¿¹Ãø(-2032³â) : À¯Çüº°, °Ë»çÀå¼Òº°, ±â¼úº°, À¯Åë ä³Îº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®
Syphilis Testing Market Forecasts to 2032 - Global Analysis By Type, Location of Testing, Technology, Distribution Channel, Application, End User, and By Geography
»óǰÄÚµå : 1822387
¸®¼­Ä¡»ç : Stratistics Market Research Consulting
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,150 £Ü 5,880,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,439,000
PDF (2-5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,350 £Ü 8,998,000
PDF & Excel (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 5ȸ±îÁö °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,628,000
PDF & Excel (Global Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ±îÁö °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀåÀº 2025³â¿¡ 24¾ï 9,000¸¸ ´Þ·¯¸¦ Â÷ÁöÇÏ¸ç ¿¹Ãø ±â°£ Áß CAGR 8.8%·Î ¼ºÀåÇϸç, 2032³â¿¡´Â 44¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸Åµ¶ °Ë»ç¶õ ¸Åµ¶À» ÀÏÀ¸Å°´Â ±ÕÀÎ Æ®·¹Æ÷³×¸¶ÆÄ¸®µã¿¡ ÀÇÇÑ °¨¿°À» È®ÀÎÇϱâ À§ÇÑ ÀÓ»óÀû ÀýÂ÷¸¦ ¸»ÇÕ´Ï´Ù. Áø´Ü ¹æ¹ý¿¡´Â ÀϹÝÀûÀ¸·Î Ç÷¾× ±â¹Ý ºñÆ®·¹Æ÷³×¸¶ °Ë»ç¿Í Æ®·¹Æ÷³×¸¶ °Ë»ç°¡ ÀÖÀ¸¸ç, º´±â °áÁ¤, °¨¿° È®ÀÎ, Ä¡·á¿¡ ´ëÇÑ È¯ÀÚÀÇ ¹ÝÀÀÀ» ÃßÀûÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ °Ë»ç´Â Áúº´ÀÇ È®»êÀ» ¸·°í, »ê¸ð¿Í ¿µÀ¯¾ÆÀÇ °Ç°­À» º¸È£Çϰí ÇÕº´ÁõÀ» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ƯÈ÷ ¼ºº´¿¡ °É¸± À§ÇèÀÌ ³ôÀº »ç¶÷À̳ª ¼ºº´¿¡ °É·ÈÀ» °¡´É¼ºÀÌ ÀÖ´Â »ç¶÷¿¡°Ô ÀÌ °Ë»ç´Â ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

Á¤±â °ËÁø ÇÁ·Î±×·¥ Áõ°¡

¸Åµ¶ °Ë»çÀÇ Á¤±âÀûÀÎ ½Ç½Ã°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç±â°üÀº ƯÈ÷ ÀÓ»êºÎ, HIV °¨¿°ÀÚ µî °íÀ§Ç豺 »çÀÌ¿¡¼­ °¨¿°À» Á¶±â¿¡ ¹ß°ßÇϱâ À§ÇÑ ³ë·ÂÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ½Å¼ÓÇÑ ÇöÀå °Ë»ç ±â¼úÀÇ ¹ßÀüÀ¸·Î Áø·á¼Ò ¹× ¾Æ¿ô¸®Ä¡ ȯ°æ¿¡¼­ÀÇ Æø³ÐÀº Àû¿ëÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. µðÁöÅÐ Çコ Ç÷§Æû°úÀÇ ÅëÇÕÀ» ÅëÇØ ȯÀÚ ÃßÀû Á¶»ç ¹× ÈÄ¼Ó Áø´ÜÀ» º¸´Ù È¿À²ÀûÀ¸·Î ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. »õ·Î¿î µ¿Çâ Áß Çϳª´Â AI¸¦ ÅëÇÑ ¼±º° ¾Ë°í¸®Áò°ú ¸ð¹ÙÀÏ ±â¹Ý °Ë»ç ŰƮ¸¦ ÅëÇØ Á¢±Ù¼ºÀ» Çâ»ó½ÃŰ´Â °ÍÀÔ´Ï´Ù. °¢±¹ Á¤ºÎ°¡ STI °¨½Ã ÇÁ·Î±×·¥À» È®´ëÇÏ´Â °¡¿îµ¥ ¸Åµ¶ °Ë»ç´Â ¿¹¹æ °Ç°­°ü¸® Àü·«ÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÒÃæºÐÇÑ ÀÇ·á ÀÎÇÁ¶ó ¹× Á¢±Ù¼º

¸¹Àº Àú¼Òµæ ±¹°¡´Â ÈÆ·ÃµÈ ÀηÂ, °Ë»ç ´É·Â, Çʼö °Ë»ç ¿ëǰÀÇ ºÎÁ·¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÎÇÁ¶ó ºÎÁ·Àº ¼±Ãµ¼º ¸Åµ¶ÀÇ Á¶±â ¹ß°ßÀÌ Áß¿äÇÑ »êÀü°ü¸® ȯ°æ¿¡¼­ ƯÈ÷ µÎµå·¯Áý´Ï´Ù. µðÁöÅÐ ¿¬°áÀÇ ºÎÁ·Àº Áß¾Ó ÁýÁᫎ ÀÇ·á ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀ» ´õ¿í Á¦ÇÑÇÕ´Ï´Ù. À̵¿Áø·á¼Ò¿Í ¿ø°ÝÀÇ·á´Â ºÎºÐÀûÀÎ ÇØ°áÃ¥À» Á¦°øÇÏÁö¸¸, È®À强ÀÌ ¹®Á¦ÀÔ´Ï´Ù. ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ°¡ ¾ø´Ù¸é ¸Åµ¶ °Ë»ç ¹üÀ§´Â Áö¿ªº°·Î ºÒ±ÕµîÇÏ°Ô À¯ÁöµÉ °ÍÀÔ´Ï´Ù.

¸ÖƼÇ÷º½º °Ë»ç ¹× ÀÌÁß °Ë»ç ÅëÇÕ

¿©·¯ STI¸¦ µ¿½Ã¿¡ °ËÃâÇÏ´Â ÀÌÁß ¸ñÀû ºÐ¼®Àº ÀÓ»ó ¹× °øÁߺ¸°Ç ºÐ¾ß¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ¼Ò¿ä ½Ã°£À» ´ÜÃàÇϰí, ºñ¿ë È¿À²¼ºÀ» °³¼±Çϸç, ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐ ¹× ¹ÙÀÌ¿À¼¾¼­ ±â¼úÀÇ ¹ßÀüÀ¸·Î ºÐ»êÇü »ç¿ë¿¡ ÀûÇÕÇÑ ¼ÒÇü ´ÙÇ׸ñ ºÐ¼®±â°¡ ½ÇÇöµÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦±â°üÀº ÀÇ·á ¼­ºñ½º Á¦°øÀ» °£¼ÒÈ­Çϱâ À§ÇØ Àϰý °Ë»ç ÇÁ·ÎÅäÄÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á°¡ ¹ßÀüÇÔ¿¡ µû¶ó ¸ÖƼÇ÷º½º ¸Åµ¶ °Ë»ç´Â Á¾ÇÕÀûÀμº °Ç°­°ËÁø¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

´Ù¸¥ STI Áø´Ü¾à°úÀÇ °æÀï

HIV, Ŭ¶ó¹Ìµð¾Æ, ÀÓÁú °Ë»ç´Â Á¾Á¾ Á¶´Þ ¿¹»ê°ú °øÁß º¸°ÇÀÇ ¿ì¼±¼øÀ§¸¦ Â÷ÁöÇÕ´Ï´Ù. ¿©·¯ º´¿øÃ¼ ÆÐ³ÎÀÌ Àü·«ÀûÀ¸·Î ¹­ÀÌÁö ¾Ê´Â ÇÑ, ¸Åµ¶¿¡ ƯȭµÈ ±â¼ú Çõ½Å¿¡ ´ëÇÑ ÁýÁßµµ°¡ ¶³¾îÁú ¼ö ÀÖ½À´Ï´Ù. ºÐÀÚÁø´Ü ¹× CRISPR ±â¹Ý °ËÃâÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î »õ·Î¿î ±â¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ÁýÁߵǰí ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ´ÜÆíÈ­´Â ƯÁ¤ °Ë»ç Çü½ÄÀ̳ª ºê·£µå¿¡ ´ëÇÑ Áö¿ªÀû ¼±È£µµ¿¡ ÀÇÇØ ¹ß»ýÇϱ⵵ ÇÕ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19´Â ÀÏ»óÀûÀÎ STI °ËÁø ÇÁ·Î±×·¥¿¡ È¥¶õÀ» ÀÏÀ¸ÄÑ Áø´ÜÀÌ Áö¿¬µÇ°í °Ë»ç Ƚ¼ö°¡ °¨¼ÒÇÏ´Â °á°ú¸¦ ÃÊ·¡Çß½À´Ï´Ù. ºÀ¼â¿Í COVID-19 Áø´Ü¾à¿¡ ´ëÇÑ ÀÚ¿øÀÇ ÀçºÐ¹è´Â °Ë»ç ½Ã¼³ÀÇ ¿ª·®°ú °ø±Þ¸Á¿¡ ±äÀåÀ» ÃÊ·¡Çß½À´Ï´Ù. ±×·¯³ª ÀÌ À§±â´Â STIÀÇ ¿ø°Ý °Ë»ç ŰƮ¿Í µðÁöÅÐ º¸°í Ç÷§ÆûÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­Çß½À´Ï´Ù. ±ä±Þ ±ÔÁ¦ Á¶Ä¡·Î ÀÚ°¡ °Ë»ç Çü½ÄÀ» Æ÷ÇÔÇÑ »õ·Î¿î ¸Åµ¶ °Ë»ç¹ýÀÇ ½Å¼ÓÇÑ ½ÂÀÎÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÇöÀç Æ÷½ºÆ® ÆÒµ¥¹Í Àü·«Àº ȸº¹·Â, ºÐ»êÇü Áø´Ü, ÆÒµ¥¹Í ´ëºñ ÇÁ·¹ÀÓ¿öÅ©¿ÍÀÇ ÅëÇÕÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ Áß ¼±Ãµ¼º ¸Åµ¶ ºÐ¾ß°¡ °¡Àå Ŭ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼±Ãµ¼º ¸Åµ¶ ºÐ¾ß´Â °øÁߺ¸°ÇÇÐÀû Á߿伺 ¶§¹®¿¡ ¿¹Ãø ±â°£ Áß °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »êÀü °ËÁø Àǹ«È­¿Í »êÀü °ü¸® ÇÁ·ÎÅäÄÝÀÇ °³¼±Àº Á¶±â ¹ß°ß Åø¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½Å¼ÓÇÑ Æ®·¹Æ÷³×¸¶ °Ë»çÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀӽŠÁß Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °¢±¹ Á¤ºÎ´Â ¼±Ãµ¼º ¸Åµ¶ ÅðÄ¡¸¦ ¿ì¼±¼øÀ§·Î »ï°í ÀÖÀ¸¸ç, ÁýÁßÀûÀÎ ÀÚ±Ý Áö¿ø°ú °¨½Ã ÇÁ·Î±×·¥À» ÅëÇØ ¸Åµ¶ ÅðÄ¡¸¦ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀüÀÚÀǹ«±â·Ï°úÀÇ ÅëÇÕÀ» ÅëÇØ ȯÀÚ ÃßÀû ¹× ÈÄ¼Ó Ä¡·á°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼±Ãµ¼º ¸Åµ¶ °Ë»ç´Â »ê¸ð¿Í ½Å»ý¾Æ °Ç°­ Àü·«ÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ Áß °øÁß º¸°Ç ÇÁ·Î±×·¥ ºÐ¾ß´Â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿¹Ãø ±â°£ Áß Àü ¼¼°è¿¡¼­ STI ´ëÀÀ ±¸»óÀÌ È®´ëµÊ¿¡ µû¶ó °øÁߺ¸°Ç ÇÁ·Î±×·¥ ºÐ¾ß°¡ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±¹°¡ ¹× Áö¿ª Ä·ÆäÀÎÀº À̵¿ À¯´Ö, Áö¿ª»çȸ ¾Æ¿ô¸®Ä¡, Çб³ ±â¹Ý °³ÀÔÀ» ÅëÇØ ¸Åµ¶ °ËÁøÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý µ¥ÀÌÅÍ ½Ã½ºÅÛ µµÀÔÀ¸·Î ÇÁ·Î±×·¥ ¸ð´ÏÅ͸µ°ú ¿ªÇÐ ÀλçÀÌÆ®°¡ °­È­µÇ°í ÀÖ½À´Ï´Ù. Àúºñ¿ë °í󸮷® °Ë»ç Ç÷§ÆûÀÇ Çõ½ÅÀ¸·Î Áý´Ü °Ë»ç°¡ ´õ¿í Çö½ÇÈ­µÇ°í ÀÖ½À´Ï´Ù. NGO, Á¤ºÎ ¹× Áø´Ü ±â¾÷ °£ÀÇ ÆÄÆ®³Ê½ÊÀ» ÅëÇØ °íºÎÇÏ Áö¿ª¿¡¼­ÀÇ ¹èÆ÷°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è °øÁߺ¸°ÇÀÇ ¿ì¼±¼øÀ§°¡ STI Á¦°Å·Î À̵¿ÇÔ¿¡ µû¶ó °øÁߺ¸°Ç ÇÁ·Î±×·¥ÀÌ ½ÃÀå È®´ëÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ÀÇ·á ÅõÀÚ Áõ°¡¿Í Àüü Àα¸ÀÇ °ËÁø¿¡ ´ëÇÑ ³ë·Â¿¡ ÈûÀÔÀº °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Áß±¹, Àεµ, Àεµ³×½Ã¾Æ µîÀÇ ±¹°¡´Â ±¹°¡ º¸°Ç ¹Ì¼Ç°ú µðÁöÅÐ Çコ ±¸ÃàÀ» ÅëÇØ STI Áø´ÜÀÇ ±Ô¸ð¸¦ È®´ëÇϰí ÀÖ½À´Ï´Ù. °Ë»ç ŰƮÀÇ ÇöÁö »ý»êÀº Àú·ÅÇÑ °¡°Ý°ú °ø±Þ¸Á ź·Â¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. »õ·Î¿î µ¿ÇâÀ¸·Î´Â AI¸¦ Ȱ¿ëÇÑ Áø´Ü Ç÷§Æû°ú ¿ø°ÝÁö¿¡ ¸Â°Ô Á¶Á¤µÈ ¸ð¹ÙÀÏ °Ë»ç½ÇÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¼¼°è ±â¾÷°ú Áö¿ª ±â¾÷°úÀÇ Àü·«Àû Á¦ÈÞ´Â ±â¼ú ÀÌÀü°ú ½ÃÀå ħÅõ¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¿¹Ãø ±â°£ Áß ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ±â¼ú ¸®´õ½Ê°ú źźÇÑ °øÁß º¸°Ç ÀÎÇÁ¶ó¿¡ ÈûÀÔÀº ¹Ù Å®´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù´Â ºÐÀÚ ¹× AI °­È­ Ç÷§ÆûÀ» Æ÷ÇÔÇÑ Â÷¼¼´ë STI Áø´Ü¾à¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦±â°üÀº ÀçÅÃÀÇ·á ¹× ¿ø°ÝÀÇ·á¿¡ ´ëÀÀÇÏ´Â Çü½ÄÀ» Æ÷ÇÔÇÑ Çõ½ÅÀûÀÎ ¸Åµ¶ °Ë»çÀÇ ½ÂÀÎÀ» °£¼ÒÈ­Çϰí ÀÖ½À´Ï´Ù. ÀüÀÚÀǹ«±â·Ï°ú ¿¹Ãø ºÐ¼®°úÀÇ ÅëÇÕÀ» ÅëÇØ »ç·Ê °ü¸®¿Í ¹ßº´ ´ëÀÀÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù. º¸Çè »óȯ ÇÁ·¹ÀÓ¿öÅ©´Â ƯÈ÷ ¼­ºñ½º°¡ ÃæºÐÇÏÁö ¾ÊÀº Áö¿ª»çȸ¿¡¼­ ÀÏ»óÀûÀÎ STI °ËÁøÀ» Á¡Á¡ ´õ ÁöÁöÇÏ´Â ¹æÇâÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ¼­¹®

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

Á¦4Àå Porters Five Force ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå : À¯Çüº°

Á¦6Àå ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå : °Ë»çÀå¼Òº°

Á¦7Àå ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå : ±â¼úº°

Á¦8Àå ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå : À¯Åë ä³Îº°

Á¦9Àå ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå : ¿ëµµº°

Á¦10Àå ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¼¼°èÀÇ ¸Åµ¶ °Ë»ç ½ÃÀå : Áö¿ªº°

Á¦12Àå ÁÖ¿ä ¹ßÀü

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to Stratistics MRC, the Global Syphilis Testing Market is accounted for $2.49 billion in 2025 and is expected to reach $4.49 billion by 2032 growing at a CAGR of 8.8% during the forecast period. Syphilis testing refers to clinical procedures aimed at identifying infection caused by Treponema pallidum, the bacterium that leads to syphilis. Diagnostic methods typically include blood-based non-treponemal and treponemal tests, which help determine disease stage, verify infection, and track patient response to treatment. This testing is vital for reducing disease spread, protecting maternal and infant health, and managing complications. It is particularly significant for individuals at higher risk or with possible exposure to sexually transmitted infections.

Market Dynamics:

Driver:

Increased routine screening programs

The rising implementation of routine syphilis screening initiatives is significantly boosting market demand. Public health agencies are intensifying efforts to detect infections early, especially among high-risk populations such as pregnant women and individuals with HIV. Technological advancements in rapid point-of-care tests are enabling broader deployment across clinics and outreach settings. Integration with digital health platforms is streamlining patient tracking and follow-up diagnostics. Emerging trends include AI-assisted screening algorithms and mobile-based testing kits that improve accessibility. As governments expand STI surveillance programs, syphilis testing is becoming a core component of preventive healthcare strategies.

Restraint:

Inadequate healthcare infrastructure and access

Many low-income countries face shortages in trained personnel, laboratory capacity, and essential testing supplies. Infrastructure gaps are especially pronounced in antenatal care settings, where early detection of congenital syphilis is critical. The lack of digital connectivity further restricts integration with centralized health systems. While mobile clinics and telemedicine offer partial solutions, scalability remains a challenge. Without sustained investment in healthcare infrastructure, syphilis testing coverage will remain uneven across geographies.

Opportunity:

Integration of multiplex and dual-purpose tests

Dual-purpose assays that detect multiple STIs simultaneously are gaining traction in both clinical and public health settings. These platforms reduce turnaround time, improve cost-efficiency, and enhance patient compliance. Advances in microfluidics and biosensor technologies are enabling compact, multi-analyte devices suitable for decentralized use. Regulatory bodies are increasingly supporting bundled testing protocols to streamline care delivery. As personalized medicine evolves, multiplex syphilis tests are expected to play a pivotal role in integrated sexual health diagnostics.

Threat:

Competition from other STI diagnostics

Tests for HIV, chlamydia, and gonorrhea often dominate procurement budgets and public health priorities. Multi-pathogen panels may dilute focus on syphilis-specific innovations unless bundled strategically. Rapid developments in molecular diagnostics and CRISPR-based detection are shifting attention toward newer technologies. Market fragmentation is also driven by regional preferences for certain test formats or brands.

Covid-19 Impact

The pandemic disrupted routine STI screening programs, leading to delayed diagnoses and reduced testing volumes. Lockdowns and resource reallocation toward Covid-19 diagnostics strained laboratory capacity and supply chains. However, the crisis accelerated adoption of remote testing kits and digital reporting platforms for STIs. Emergency regulatory pathways enabled faster approval of novel syphilis assays, including self-testing formats. Post-pandemic strategies now emphasize resilience, decentralized diagnostics, and integration with pandemic preparedness frameworks.

The congenital syphilis segment is expected to be the largest during the forecast period

The congenital syphilis segment is expected to account for the largest market share during the forecast period, due to its critical public health implications. Rising maternal screening mandates and improved prenatal care protocols are driving demand for early detection tools. Technological advances in rapid treponemal tests are enabling timely intervention during pregnancy. Governments are prioritizing congenital syphilis elimination through targeted funding and surveillance programs. Integration with electronic health records is improving case tracking and follow-up treatment. As awareness grows, congenital syphilis testing is becoming a cornerstone of maternal and neonatal health strategies.

The public health programs segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the public health programs segment is predicted to witness the highest growth rate, driven by expanding STI control initiatives worldwide. National and regional campaigns are scaling up syphilis screening through mobile units, community outreach, and school-based interventions. Adoption of cloud-based data systems is enhancing program monitoring and epidemiological insights. Innovations in low-cost, high-throughput testing platforms are making mass screening more feasible. Partnerships between NGOs, governments, and diagnostic firms are accelerating deployment in high-burden areas. As global health priorities shift toward STI elimination, public health programs will be central to market expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare investments and population-wide screening efforts. Countries like China, India, and Indonesia are scaling up STI diagnostics through national health missions and digital health rollouts. Local manufacturing of test kits is improving affordability and supply chain resilience. Emerging trends include AI-powered diagnostic platforms and mobile testing labs tailored for remote regions. Strategic collaborations between global and regional players are enhancing technology transfer and market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological leadership and robust public health infrastructure. The U.S. and Canada are investing heavily in next-gen STI diagnostics, including molecular and AI-enhanced platforms. Regulatory agencies are streamlining approvals for innovative syphilis tests, including home-based and telehealth-compatible formats. Integration with electronic medical records and predictive analytics is improving case management and outbreak response. Reimbursement frameworks are increasingly supportive of routine STI screening, especially in underserved communities.

Key players in the market

Some of the key players profiled in the Syphilis Testing Market include Abbott Laboratories, SD Biosensor, Roche Diagnostics, Trinity Biotech, Siemens Healthineers, MedMira Inc., Thermo Fisher Scientific, Fujirebio, Bio-Rad Laboratories, QuidelOrtho Corporation, Danaher Corporation, bioMerieux, Becton, Dickinson and Company (BD), OraSure Technologies, and Hologic Inc.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH.

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Types Covered:

Location of Testings Covered:

Technologies Covered:

Distribution Channels Covered:

Applications Covered:

End Users Covered:

Regions Covered:

What our report offers:

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Table of Contents

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porters Five Force Analysis

5 Global Syphilis Testing Market, By Type

6 Global Syphilis Testing Market, By Location of Testing

7 Global Syphilis Testing Market, By Technology

8 Global Syphilis Testing Market, By Distribution Channel

9 Global Syphilis Testing Market, By Application

10 Global Syphilis Testing Market, By End User

11 Global Syphilis Testing Market, By Geography

12 Key Developments

13 Company Profiling

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â